MINI LONG - BIOARCTIC B | Real-time Bid/Ask 06:55:01 2024-05-23 am EDT | ||
| 80.75 SEK / 82.21 SEK | +9.33% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOARCTIC AB
Latest news about BIOARCTIC AB
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 74.53 | -7.92% |
| 24-05-20 | 80.94 | +3.60% |
| 24-05-17 | 78.13 | -2.64% |
| 24-05-16 | 80.25 | +0.34% |
| 24-05-15 | 79.98 | +39.31% |
Delayed Quote Nasdaq Stockholm
Last update May 21, 2024 at 08:16 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOARCTIC AB |
| Issuer | Morgan Stanley |
| MINI L BIOARCTI | |
| ISIN | GB00BSJJQP03 |
| Date issued | 2024-04-25 |
| Strike | 152.9 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - kr |
| Emission volume | N/A |
| Settlement | cash |
| Currency | SEK |
Technical Indicators
| Highest since issue | 89.05 kr |
|---|---|
| Lowest since issue | 47.84 kr |
| Spread | 1.46 kr |
| Spread % | 1.76% |
Company Profile
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Sector
-
Consensus: BioArctic AB
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
223
SEK
Average target price
368
SEK
Spread / Average Target
+65.02%
- Stock Market
- Certificates
- MINI L BIOARCTI Certificat
